Pyrroloazepine derivatives
AssigneeSuntory Limited
InventorsAkira Mizuno, Hidetsura Cho, Mikiko Hamaguchi, Toshio Tatsuoka, Takafumi Ishihara
Life of this patent
Estimating the term…
Abstract
Disclosed herein are pyrroloazepine derivatives, which are useful as therapeutics for circulatory diseases, represented by the following formula (I): ##STR1## wherein R means a hydrogen atom, a linear or branched C.sub.1-6 alkyl group or a C.sub.7-10 aralkyl group, A denotes a linear or branched C.sub.2-10 alkylene, alkenylene or alkynylene group, Z stands for O, NOR.sub.1 or NOCOR.sub.5 in which R.sub.1 and R.sub.5 is a hydrogen atom or an alkyl, aryl or aralkyl group, and Y means a particular piperidinyl or pyrrolidinyl group; and salts thereof. Their preparation processes are also disclosed.
Claims9
A pyrroloazepine derivative represented by the following formula (I):
- ##STR94## wherein R means a hydrogen atom, a linear or branched C.sub.1-6 alkyl group or a C.sub.7-10 aralkyl group, A denotes a linear or branched C.sub.2-10 alkylene, alkenylene or alkynylene group, Z stands for O, NOR.sub.1 in which R.sub.1 is a hydrogen atom or an alkyl, aryl or aralkyl group, or NOCOR.sub.5 in which R.sub.5 is a hydrogen atom or an alkyl, aryl or aralkyl group, and Y means a group ##STR95## in which R.sub.2 means a hydrogen atom or a cyano group, R.sub.3 and R'.sub.3 may be the same or different and individually denote a substituted or unsubstituted phenyl group or a substituted or unsubstituted aralkyl group, and B is an oxygen or sulfur atom or a carbonyl, substituted or unsubstituted hydroxymethylene, sulfinyl, sulfonyl or substituted or unsubstituted, cyclic or acyclic acetal;
- wherein said substituents are selected from the group consisting of lower alkyl, phenyl and phenyl substituted by at least one halogen atom or C.sub.1-4 alkoxy group;
- and n stands for 0 or 1;
- or a salt thereof.
An intermediate suitable for use in the production of a pharmaceutical product, said intermediate being represented by the following formula (III):
- ##STR97## wherein A denotes a linear or branched C.sub.2-10 alkylene, alkenylene or alkynylene group, R means a hydrogen atom, a linear or branched C.sub.1-6 alkyl group or a C.sub.7-10 aralkyl group, and X represents a substituent selected from the group consisting of halogen, methanesulfonyl and p-toluenesulfonyl.
An intermediate suitable for use in the production of a pharmaceutical product, said intermediate being represented by the following formula (X):
- ##STR98## wherein A denotes a linear or branched C.sub.2-10 alkylene, alkenylene or alkynylene group, R means a hydrogen atom, a linear or branched C.sub.1-6 alkyl group or a C.sub.7-10 aralkyl group, R.sub.1 is a hydrogen atom or an alkyl, aryl or aralkyl group, and X represents a substituent selected from the group consisting of halogen, methanesulfonyl and p-toluenesulfonyl.
An intermediate suitable for use in the production of a pharmaceutical product, said intermediate being represented by the following formula (II'):
- ##STR99## wherein R' means a linear or branched C.sub.1-6 alkyl group or a C.sub.7-10 aralkyl group.
An intermediate suitable for use in the production of a pharmaceutical product, said intermediate being represented by the following formula (XII):
- ##STR100## wherein A denotes a linear or branched C.sub.2-10 alkylene, alkenylene or alkynylene group, R means a hydrogen atom, a linear or branched C.sub.1-6 alkyl group or a C.sub.7-10 aralkyl group, R.sub.5 is a hydrogen atom or an alkyl, aryl or aralkyl group, and X represents a substituent selected from the group consisting of halogen, methanesulfonyl and p-toluenesulfonyl.
Dependencies are inferred from the claim text.